How profitable is Rapid Micro Biosystems Inc. (Class A) (RPID)?

In FY 2025 (10-K), RPID converted $33.6M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / RPID / financials

HBIO (47) PRPO (30) EYPT (26) BNGO (29) ⌘ Pro Terminal →

Rapid Micro Biosystems Inc. (Class A) (RPID) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.70 -4.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.69

Rapid Micro Biosystems Inc. (Class A) (RPID) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $36.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RPID Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RPID stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Rapid Micro Biosystems Inc. (Class A) (NASDAQ: RPID) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.70 (-4.50% 1D, market cap $36.9M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RPID ranks #645 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RPID compare to HBIO and PRPO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), RPID carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HBIO (Harvard Bioscience Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $40.5M) and PRPO (Precipio Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -7.9%, cap $32.4M). Among the 5-stock peer group, RPID leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RPID?

▼

Per RPID's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001380106), Rapid Micro Biosystems Inc. (Class A) generated $33.6M in revenue (+19.7% YoY), -$47.1M in net income, and -$31.9M in free cash flow against $74.9M in total assets and $18.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.69 (-1.00%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RPID)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY RPID SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.87-11.5% Next Q

Q2 (-2Q)

Grade E$0.77+2.6% Next Q

Q3 (-1Q)

Grade E$0.79-11.4% Next Q

Current

Grade E$0.70-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RPID Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RPID currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.06) and Max Pain ($0.74) forces dealer call-delta covering toward $5.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RPID• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RPID Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How RPID Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $22.5M

FY24

Rev $28.1M

FY25

Rev $33.6M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$33.6M	52%	-80%	-$47.1M	-$31.9M	-45%
FY 2024	$28.1M	52%	-80%	-$46.9M	-$45.5M	-45%
FY 2023	$22.5M	52%	-80%	-$52.5M	-$45.1M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RPID)

✓Walkthrough of RPID's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RPID // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -71.89%🛡️ HOLDING TREND SUPPORT

2026-11-03O $0.79H $0.79L $0.70C $0.70VOL 201.6K

RES: $1.64SUP: $0.64SMA50: $1.06SMA200: $2.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RPID Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RPID Butterfly Map → + Track RPID →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +19.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RPID today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RPID. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RPID today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RPID)

Health Care Rank #645 of 1016 ⚔️ HBIO vs RPID Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RPID vs. HBIO, PRPO, EYPT, BNGO)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rapid Micro Biosystems Inc. (Class A) (RPID) ranks #645 by composite RQD confidence (34/100, grade E) and #778 by equity capitalization ($36.9M). Within this direct 5-issuer industry benchmark cohort, RPID leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. HBIO currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with RPID at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RPID ACTIVE Rapid Micro Biosystems Inc. (Class A)	E	34/100	—	—	-35.0%	-4.50%	$36.9M	Benchmark Subject
HBIO Harvard Bioscience Inc.	D	47/100	—	57.7%	-35.0%	-3.37%	$40.5M	/hbio-vs-rpid →
PRPO Precipio Inc.	E	30/100	—	44.2%	-7.9%	-1.71%	$32.4M	/prpo-vs-rpid →
EYPT EyePoint Inc.	E	26/100	—	—	-35.0%	+7.58%	$30.0M	/eypt-vs-rpid →
BNGO Bionano Genomics Inc.	E	29/100	—	46.3%	-35.0%	+0.87%	$16.1M	/bngo-vs-rpid →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001380106

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rapid Micro Biosystems Inc. (Class A) (RPID) reported GAAP revenue of $33.6M (+19.7% vs. FY2024 revenue of $28.1M , and +49.1% cumulative change since FY2023) , GAAP net income of -$47.1M, operating cash flow of -$31.1M, and free cash flow of -$31.9M (+29.9% YoY). On the balance sheet, RPID closed FY2025 with $74.9M in total assets against $18.9M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$33.6M	-$47.1M	-$31.1M	-$31.9M	$74.9M	$18.9M
FY2024 (FY)	2024-12-31	$28.1M	-$46.9M	-$44.2M	-$45.5M	$98.2M	$0
FY2023 (FY)	2023-12-31	$22.5M	-$52.5M	-$45.1M	-$45.1M	—	—

3. RPID Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RPID stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RPID compare to HBIO and PRPO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RPID?

Where is RPID trading relative to its 50-day, 200-day, and 52-week technical levels?

RPID last traded at $0.70 (-4.50% on volume of 77,267 shares), positioning the stock -33.96% below its 50-day simple moving average ($1.06) and -68.33% below its 200-day simple moving average ($2.21). Across its 52-week range of $0.70 to $4.94, RPID sits at the 0.0% percentile with a 14-day RSI of 31.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.79).

Direct Sub-Reports: RPID RQD Cockpit RPID 12M Forecast RPID Earnings & Move RPID Dividends & DRIP RPID Insiders & 13F RPID Whale Options RPID Profit Sankey RPID News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RPID — Rapid Micro Biosystems Inc. (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:47:45Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

RPID scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillar scores are:

Fundamental Cash Engine: 9 / 20 (ROIC -35%; FCF yield 0%). This is the weakest economic signal in the rating: the business is not currently generating a return on invested capital or free cash flow relative to its valuation.
Whale 13F Flow: 4 / 20 (institutional accumulation and options positioning). This is the lowest pillar score and indicates little supportive institutional positioning in the source data.
Insider Conviction: 5 / 20 (SEC Form 4 and Congressional PTR cluster flow). Insider signal is weak in the source data.
Macro Regime Fit: 7 / 20 (Beta 1.0; sector sensitivity). The rating reflects a market-neutral beta with limited macro tailwind in the scoring.
Forensic Balance Sheet: 11 / 20 (Altman Z 2.5; Piotroski F 4/9; Debt/Equity 0.57). This is the strongest pillar, but it remains only moderate.

For a prospective investor evaluating the stock today, the implication is that the rating reflects weak cash generation, thin institutional and insider support, and a balance sheet that is serviceable but not strong.6M against reported operating losses. This is an educational summary of the scoring, not personalized financial advice.

2. Business Model, Unit Margins & SEC Financial Trajectory

Rapid Micro Biosystems Inc. (Class A) is a NASDAQ-listed Health Care issuer in the Biotechnology: Laboratory Analytical Instruments industry. Specific product lines, customer segments, and revenue model details are — The reported revenue figures in the SEC financials indicate an operating business with $33.6M of FY 2025 revenue, but the source does not describe how that revenue is generated.

Revenue grew from $22.5M in FY 2023 to $33.6M in FY 2025, while operating losses remained large in each period. Per the market data, operating margin and net margin are both -60%, gross margin is 0%, and ROIC is -35%. The Altman Z-Score is 2.5, the Piotroski F-Score is 4/9, and Debt/Equity is 0.57. Cash of $20.0M against debt of $18.9M, per the FY 2025 SEC financials, describes a balance sheet with limited cushion relative to continued operating losses.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Revenue grew from $22.5M in FY 2023 to $33.6M in FY 2025, and the forensic balance sheet pillar scores 11 / 20 on Altman Z 2.5 and Debt/Equity 0.57. With Fundamental Cash Engine at 9/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $0.70 – $4.94 52-week range.
🐻 Primary Bear Case: FY 2025 free cash flow of -$31.9M against $20.0M of cash, with ROIC at -35% and operating margin at -60%, leaves the cash engine pillar at 9 / 20. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream links, no sector correlations, and no proprietary signals in the source data. Upstream/downstream dependencies: — Sector correlations: — 2nd-order bottlenecks: — The only sector information available is the Health Care / Biotechnology: Laboratory Analytical Instruments classification.

Key Question #1: What is the company's cash runway given FY 2025 FCF of -$31.9M against cash of $20.0M?
Key Question #2: What drove the revenue increase from $28.1M to $33.6M, and is it recurring?
Key Question #3: What is the status of the Q3 earnings release, and does the negative-earnings headline reflect current expectations?

RPID Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Rapid Micro Biosystems Inc. (Class A) (RPID) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RPID Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 20h ago

Rapid Micro Biosystems, Inc. (RPID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Yahoo Finance report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 23h ago

Rapid Micro Biosystems to Participate at the PDA Pharmaceutical Microbiology Conference 2026

Yahoo Finance report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

RPID Q3'26 Earnings: revenue estimate is 9.88M USD

TradingView report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Rapid Micro Biosystems stock: PDA event spotlights Rapid Micro Biosystems stock on October 26

ad-hoc-news.de report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Largest Companies by Market Cap: U.S. Stocks

TradingKey report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Rapid Infection Diagnostics Appoints Mario Savarese to Strategic Advisory Board

Yahoo Finance report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

RPID Q2 2026 Earnings: Wider-Than-Expected Loss Pressures Shares - Earnings Weakness Phase

https://www.dars.gov.et/ report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

RPID Q2 2026 Earnings: Wider-Than-Expected Loss, Yet Shares Edge Higher - Profit Growth Outlook

https://www.dars.gov.et/ report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RPID Bull vs. Bear Conversation Board — What's Your Call at $0.70?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RPID 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $0.96 (+29.7%)

📌 Pinned Debate

Revenue grew from $22.5M in FY 2023 to $33.6M in FY 2025, and the forensic balance sheet pillar scores 11 / 20 on Altman Z 2.5 and Debt

Here is why I am bullish on RPID here at $0.74: Revenue grew from $22.5M in FY 2023 to $33.6M in FY 2025, and the forensic balance sheet pillar scores 11 / 20 on Altman Z 2.5 and Debt/Equity 0.57.. Compare RPID's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Laboratory Analytical Instruments. As long as cash conversion holds up, dips toward $0.70 are getting bought.

RetailWhale_TX 🐂 BULL

@MultipleCompression Shorting a 3/20 institutional whale-flow stock at $0.74 is dangerous when funds are rotating into Health Care.

MU MultipleCompression Valuation Discipline 🐻 BEARISH 🎯 Target: $0.62 (-16.2%)

Spot @ $0.74

FY 2025 free cash flow of -$31.9M against $20.0M of cash, with ROIC at -35% and operating margin at -60%, leaves the cash engine pillar

I respect the product at Rapid Micro Biosystems Inc. (Class A), but the stock at $0.74 is a different story. FY 2025 free cash flow of -$31.9M against $20.0M of cash, with ROIC at -35% and operating margin at -60%, leaves the cash engine pillar at 9 / 20.. FCF yield is 0.0% and RQD sits at 34/100 (E) — why pay up here when you can wait for next quarter's numbers?